Address
Quaker BioVentures Inc
2929 Arch Street
Cira Centre
Philadelphia, PA 19104
United States
Phone
Email
Website
Recent investment activity
KANDO id: 27817
Funding rounds
Actual initial investment stage
N/A (2)
Investment activity status
Active investor
Selected investments
Displaying 26 - 45 of 45| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Semprae Laboratories Inc | Commercializing consumer products for female sexual health, including lead product Zestra® | N/A | |||
|
|
Sleep Solutions Inc | N/A | ||||
|
|
TargetRx Inc | Provider of insight to the pharmaceutical and biotech enterprises into the drivers of prescribing. | N/A | |||
|
|
Tarsa Therapeutics Inc | Developer of an oral formulation of calcitonin for the treatment of osteoporosis | N/A | |||
|
|
Tengion Inc | A leading regenerative medicine company. | N/A | |||
|
|
TetraLogic Pharmaceuticals | A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. | Series B | |||
|
|
Transave Inc | N/A | ||||
|
|
TransEnterix Inc | Medical device company focused on innovative techniques and tools for minimally invasive surgery. | N/A | |||
|
|
Tranzyme Pharma | Drug discovery and development, focused on gastroenterology indications | N/A | |||
|
|
Tranzyme Pharma | Drug discovery and development, focused on gastroenterology indications | N/A | |||
|
|
Achillion Pharmaceuticals Inc | Biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. | N/A Initial investment | |||
|
|
Amicus Therapeutics Inc | N/A Initial investment | ||||
|
|
Biolex Therapeutics Inc | Series D | ||||
|
|
Biolex Therapeutics Inc | Series C | ||||
|
|
Biolex Therapeutics Inc | Series B | ||||
|
|
Celator Pharmaceuticals | Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers. | Series D | |||
|
|
Celator Pharmaceuticals | Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers. | Series C | |||
|
|
Celator Pharmaceuticals | Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers. | N/A | |||
|
|
TearScience Inc | Developer of a diagnostic and treatment devices targeted at the root cause of the majority of dry eye cases. | Series C | |||
|
|
TetraLogic Pharmaceuticals | A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. | Series C |